.jpg)
Among the good news for Regeneron (REGN) shareholders were strong sales for a treatment for eye diseases. Total revenue jumped fourfold last quarter.
The Tarrytown, N.Y.-based company also won approval for a chemotherapy drug and is developing drugs to treat rheumatoid arthritis and high cholesterol.
Universe and criteria: 358 stocks on U.S. exchanges with market capitalizations of more than $10 billion.
No comments:
Post a Comment